Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + olaparib
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cabozantinib + olaparib is a combination of two small molecule drugs used in oncology research and clinical trials. Cabozantinib is a multi-targeted tyrosine kinase inhibitor that blocks several receptor tyrosine kinases involved in tumor growth, angiogenesis, and metastatic progression, including MET, VEGFR2, AXL, and RET. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that impairs DNA repair by inhibiting PARP enzymes, leading to cell death in cancer cells with deficient homologous recombination repair mechanisms such as those with BRCA mutations. This combination aims to exploit complementary mechanisms—targeting both tumor cell survival pathways and DNA repair—to enhance antitumor efficacy. Both drugs are approved individually for various cancers; their combination is under investigation for synergistic effects in solid tumors.
- Other names
- XL184 (for cabozantinib)AZD2281 (for olaparib)
02
Targets
AXL (AXL receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)TEK (Tie2)VEGFR2 (Vascular endothelial growth factor receptor 2)MET (Mesenchymal-epithelial transition factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on cabozantinib + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + olaparib.